Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Renvela on AZD1722 Pharmacodynamics
NCT02346890Phase 1Completed
- Sponsor
- Ardelyx
- Start
- Apr 2013
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenapanor in hyperphosphatemia (2 arms), sponsored by Ardelyx. Primary endpoint: Sodium levels in stool and urine at 4 days. Started Apr 2013; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02346890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346890.